Tandem Diabetes Company Leadership

TNDM Stock  USD 35.15  2.38  6.34%   
Tandem Diabetes employs about 2.4 K people. The company is managed by 15 executives with a total tenure of roughly 30 years, averaging almost 2.0 years of service per executive, having 160.0 employees per reported executive. Analysis of Tandem Diabetes' management performance can provide insight into the firm performance.
Brian Hansen  President
Chief Commercial Officer, Executive Vice President
Leigh Vosseller  President
Senior Vice President - Finance

Tandem Diabetes' Insider Buying Vs Selling

50

 
Selling
 
Buying

Latest Trades

2024-11-20Kim D BlickenstaffDisposed 10000 @ 30View
2024-11-15Mark David NovaraAcquired 532 @ 23.24View
2024-08-05Josh GottheimerAcquired @ 40.79
2024-05-30Dick AllenDisposed 5000 @ 51.68View
Monitoring Tandem Diabetes' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Tandem Diabetes' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Tandem Diabetes Care. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Tandem Diabetes' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Tandem Diabetes' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Tandem Diabetes' future performance. Based on our forecasts, it is anticipated that Tandem will maintain a workforce of about 2400 employees by February 2025.
 
Yuan Drop
 
Covid

Tandem Diabetes' latest congressional trading

Congressional trading in companies like Tandem Diabetes Care, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Tandem Diabetes by those in governmental positions are based on the same information available to the general public.
2024-09-11Representative Josh GottheimerAcquired Under $15KVerify

Tandem Diabetes Management Team Effectiveness

The company has return on total asset (ROA) of (0.0969) % which means that it has lost $0.0969 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4596) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of January 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to grow to -0.34. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 17th of January 2025, Net Tangible Assets is likely to grow to about 531.2 M, while Intangibles To Total Assets are likely to drop 0.
As of the 17th of January 2025, Common Stock Shares Outstanding is likely to grow to about 78.5 M, while Net Loss is likely to drop (114.2 M).

Tandem Diabetes Workforce Comparison

Tandem Diabetes Care is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 353,436. Tandem Diabetes maintains roughly 2,400 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11.

Tandem Diabetes Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tandem Diabetes insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.6053
23
38
 51,639 
 108,121 
2024-09-01
0.5143
18
35
 62,962 
 33,996 
2024-06-01
1.0294
70
68
 477,258 
 166,510 
2024-03-01
0.5135
19
37
 10,832 
 14,681 
2023-12-01
0.6939
34
49
 114,872 
 15,954 
2023-09-01
0.5306
26
49
 13,793 
 16,907 
2023-06-01
1.1695
69
59
 437,790 
 65,294 
2023-03-01
2.1111
38
18
 41,242 
 13,820 
2022-12-01
2.3125
37
16
 63,718 
 12,592 
2022-09-01
1.5714
22
14
 8,505 
 2,030 
2022-06-01
3.6667
88
24
 280,092 
 27,913 
2022-03-01
1.4211
27
19
 35,888 
 11,029 
2021-12-01
1.641
64
39
 284,976 
 1,152,208 
2021-09-01
0.963
52
54
 248,884 
 354,093 
2021-06-01
0.9818
54
55
 178,226 
 239,874 
2021-03-01
0.2727
3
11
 13,354 
 220,292 
2020-12-01
0.2273
10
44
 74,872 
 385,804 
2020-09-01
0.4674
43
92
 867,069 
 1,440,806 
2020-06-01
1.3333
28
21
 176,738 
 119,308 
2020-03-01
0.5854
24
41
 181,555 
 365,656 
2019-12-01
0.3846
5
13
 50,462 
 255,924 
2019-09-01
0.4483
13
29
 80,955 
 534,025 
2019-06-01
1.0625
17
16
 57,450 
 104,688 
2019-03-01
0.5556
20
36
 1,058,982 
 574,521 
2018-12-01
1.0625
17
16
 228,749 
 482,699 
2018-06-01
2.6667
8
3
 1,035,700 
 418,144 
2018-03-01
1.5
12
8
 1,958,121 
 114,236 
2016-09-01
0.5
1
2
 15,000 
 30,000 
2016-06-01
1.5
6
4
 15,415 
 8,000 
2016-03-01
1.8333
11
6
 753,250 
 16,000 
2015-12-01
2.5
10
4
 142,000 
 12,000 
2015-09-01
0.2857
2
7
 19,500 
 94,000 
2015-06-01
3.0
12
4
 449,838 
 8,000 
2015-03-01
0.5
3
6
 6,000 
 12,000 
2014-12-01
2.5714
18
7
 158,118 
 14,000 
2014-09-01
0.5
3
6
 6,000 
 12,000 
2014-06-01
4.0
8
2
 17,945 
 4,000 
2013-12-01
0.6381
67
105
 44,225,721 
 21,266,459 
2009-03-01
0.2
1
5
 3,169 
 4,044,302 
2007-12-01
0.6154
8
13
 13,860,388 
 20,860,582 

Tandem Diabetes Notable Stakeholders

A Tandem Diabetes stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tandem Diabetes often face trade-offs trying to please all of them. Tandem Diabetes' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tandem Diabetes' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian HansenChief Commercial Officer, Executive Vice PresidentProfile
Leigh VossellerSenior Vice President - FinanceProfile
JeanClaude KyrillosExecutive COOProfile
John SheridanCOO and Executive VPProfile
Shannon JDChief VPProfile
Tom FoxChief OfficerProfile
Susan MorrisonChief Admin. OfficerProfile
Mark NovaraExecutive OfficerProfile
Ross SylviaVP MarketingProfile
David EsqTransitional AdvisorProfile
Jordan MDChief OfficerProfile
Libba SapitskySenior CareProfile
Rick CarpenterChief OfficerProfile
Elizabeth GasserExecutive OfficerProfile
Shannon HansenPrivacy LegalProfile

About Tandem Diabetes Management Performance

The success or failure of an entity such as Tandem Diabetes Care often depends on how effective the management is. Tandem Diabetes management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tandem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tandem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.35)(0.34)
Return On Assets(0.21)(0.22)
Return On Equity(0.82)(0.78)

Tandem Diabetes Workforce Analysis

Traditionally, organizations such as Tandem Diabetes use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tandem Diabetes within its industry.

Tandem Diabetes Manpower Efficiency

Return on Tandem Diabetes Manpower

Revenue Per Employee311.5K
Revenue Per Executive49.8M
Net Loss Per Employee92.8K
Net Loss Per Executive14.8M
Working Capital Per Employee230.3K
Working Capital Per Executive36.8M
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(1.94)
Revenue Per Share
13.082
Quarterly Revenue Growth
0.314
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.